A5090289526- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Inflammatory Biomarkers in Disease Prognosis
- COVID-19 and healthcare impacts
- Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Occupational and environmental lung diseases
- Colorectal Cancer Treatments and Studies
- Radiomics and Machine Learning in Medical Imaging
- Pleural and Pulmonary Diseases
- Cutaneous Melanoma Detection and Management
- Melanoma and MAPK Pathways
- Global Cancer Incidence and Screening
- Ocular Oncology and Treatments
- COVID-19 Clinical Research Studies
- Immunotherapy and Immune Responses
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Lymphoma Diagnosis and Treatment
- Medical Imaging and Pathology Studies
- Brain Metastases and Treatment
- Multiple and Secondary Primary Cancers
- Esophageal Cancer Research and Treatment
- Gastric Cancer Management and Outcomes
Hospital Clínico Universitario de Valladolid
2016-2025
Universidad de Valladolid
2019-2024
Spanish Ovarian Cancer Research Group
2024
Imperial College London
2023
Centre Hospitalier de l’Université de Montréal
2023
Instituto Nacional de Cardiologia
2023
Institut Català d'Oncologia
2023
Hospital Universitario Puerta de Hierro Majadahonda
2023
Hospital Universitario La Paz
2023
Centro de Investigación del Cáncer
2023
Approximately 20% of patients with non-small-cell lung cancer (NSCLC) receive a diagnosis stage III disease. There is no current consensus regarding the most appropriate treatment for these patients.In this open-label, phase 2 trial, we randomly assigned resectable IIIA or IIIB NSCLC to neoadjuvant nivolumab plus platinum-based chemotherapy (experimental group) alone (control group), followed by surgery. Patients in experimental group who had R0 resections received adjuvant 6 months. The...
•First randomised, controlled trial evaluating efficacy of an anti-PD1 agent versus chemotherapy in relapsed MPM, with immunotherapy crossover allowed.•Objective response rate was significantly improved for pembrolizumab (22% 6%, P = 0.004).•No improvement independently reviewed PFS over (HR 1.06, 95% CI: 0.73–1.53, 0.76).•No overall survival 1.04, 0.66–1.67, 0.85). BackgroundMalignant pleural mesothelioma (MPM) is aggressive malignancy characterised by limited treatment options and a poor...
This study aimed to assess the efficacy of combination nivolumab (nivo) plus ipilimumab (ipi) as a first-line therapy with respect 12-month overall survival (OS) in patients metastatic uveal melanoma (MUM) who are not eligible for liver resection.This was single-arm, phase II trial led by Spanish Multidisciplinary Melanoma Group (GEM) on nivo ipi systemic treatment-naïve age > 18 years, histologically confirmed MUM, Eastern Cooperative Oncology Group-PS 0/1, and progressive disease (M1)....
The Atezo-Brain study evaluated atezolizumab combined with chemotherapy in patients advanced non-small-cell lung cancer (NSCLC) untreated brain metastases, a population traditionally excluded from trials.This single-arm phase II clinical trial enrolled nonsquamous NSCLC metastases without neurologic symptoms or asymptomatic medical treatment. Dexamethasone was allowed up to 4 mg once daily. Atezolizumab plus carboplatin and pemetrexed given for four six cycles followed by until progression...
Lung cancer remains a leading cause of incidence and mortality worldwide. Although Spain contributes to global statistics related cancer, it is difficult discern aspects linked clinical presentation the disease or molecular testing. The Thoracic Tumor Registry (TTR) was created with aim filling this gap.Observational cohort multicenter study performed in Spain, including patients lung other types thoracic tumors undergoing active treatment palliative care only. Enrollment took place between...
BackgroundLung cancer is currently the leading cause of death. Despite its high incidence and mortality, there are few studies describing symptoms at diagnosis broken down by tumour stage tobacco use. Accordingly, this study was proposed to describe frequency most common non-small cell lung small (SCLC) diagnosis, with a breakdown use.Patients methodsCases were collected from Spanish Thoracic Tumour Registry, nationwide registry sponsored Lung Cancer Group. More than 50 hospitals recruited...
Patients with cancer may be at increased risk of more severe COVID-19 disease; however, prognostic factors are not yet clearly identified. The GRAVID study aimed to describe clinical characteristics, outcomes, and predictors poor outcome in patients lung COVID-19.Prospective observational that included medical records PCR-confirmed diagnosis across 65 Spanish hospitals. primary endpoint was all-cause mortality; secondary endpoints were hospitalization admission intensive care units (ICU).A...
Combined BRAF/MEK inhibition with encorafenib (E) plus binimetinib (B) has demonstrated efficacy and tolerability in phase III clinical trials, is the standard of care for advanced/metastatic BRAFV600-mutant melanoma. However, real-life evidence limited, particularly patients pre-treated immune checkpoint inhibitors (ICI). BECARE GEM 2002 was a retrospective, non-interventional study aimed at investigating real-world effectiveness EB unresectable or metastatic melanoma conducted 21 sites...
Background Small-cell lung cancer (SCLC) is an aggressive disease with high metastatic potential and poor prognosis. Due to its low prevalence, epidemiological clinical information of SCLC patients retrieved from registries scarce. Patients methods This was observational multicenter study that enrolled thoracic tumors, recruited August 2016 January 2020 at 50 Spanish hospitals. Demographic data, treatment patterns survival included in the Thoracic Tumor Registry (TTR) were analyzed. Results...
Recent advances in the treatment of locally advanced NSCLC have led to changes standard care for this disease. For selection best approach strategy each patient, it is necessary homogenization diagnostic and therapeutic interventions, as well promotion evaluation patients by a multidisciplinary oncology team.